Atara Biotherapeutics, Inc. (ATRA)

Market Cap	76.93M
Revenue (ttm)	199.73M
Net Income (ttm)	-15.64M
Shares Out	6.80M
EPS (ttm)	-1.78
PE Ratio	n/a
Forward PE	6.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,048
Open	11.43
Previous Close	11.55
Day's Range	11.20 - 11.60
52-Week Range	5.01 - 18.71
Beta	0.26
Analysts	Strong Buy
Price Target	20.00 (+76.68%)
Earnings Date	Aug 15, 2025

About ATRA

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queenslan...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2014
• Employees: 153
• Stock Exchange: NASDAQ
• Ticker Symbol: ATRA
• Website: https://www.atarabio.com

Financial Performance

In 2024, Atara Biotherapeutics's revenue was $128.94 million, an increase of 1404.02% compared to the previous year's $8.57 million. Losses were -$85.40 million, -69.07% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for ATRA stock is "Strong Buy." The 12-month stock price target is $20.0, which is an increase of 76.68% from the latest price.

Price Target

$20.0

(76.68% upside)

Analyst Consensus: Strong Buy